Delving into the Latest Updates on Glycididazole Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CMNa, Sodium Glycididazole, 希美纳

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases

Active Indication

Esophageal CarcinomaHead and Neck NeoplasmsLung Cancer

Inactive Indication-

Originator Organization

Guangzhou Lifetech Pharmaceuticals Co. Ltd.

Active Organization

Guangzhou Lifetech Pharmaceuticals Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (29 Nov 2002),

Esophageal CarcinomaHead and Neck NeoplasmsLung Cancer

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC18H23N7NaO10

InChIKeyIYDJZIUQEVRLTI-UHFFFAOYSA-N

CAS Registry173357-17-0

View All Structures (2)

This is a perspective, multicenter,single arm, open label study to evaluate the efficacy and safety of treatment with CMNa combined with preoperatie concurrent chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma . Analyses of primary objective (pathologic Complete Response) will be done as defined in the protocol.

Start Date01 Aug 2016

Sponsor / Collaborator

Shandong Cancer Hospital

100 Clinical Results associated with Glycididazole Sodium

Login to view more data

100 Translational Medicine associated with Glycididazole Sodium

Login to view more data

100 Patents (Medical) associated with Glycididazole Sodium

Login to view more data

93

Literatures (Medical) associated with Glycididazole Sodium

05 Jul 2021·Angewandte Chemie International EditionQ1 · CHEMISTRY

ZIF‐Based Nanoparticles Combine X‐Ray‐Induced Nitrosative Stress with Autophagy Management for Hypoxic Prostate Cancer Therapy

Q1 · CHEMISTRY

Article

Author: Li, Yanli ; Bu, Wenbo ; Jiang, Yaqin ; Wang, Kun ; Zheng, Xiangpeng ; Chen, Yang ; Gao, Hongbao ; Li, Huiyan ; Gong, Teng ; Wu, Yelin ; Zhao, Peiran

AbstractAlthough reactive oxygen species (ROS)‐mediated tumor treatments are predominant in clinical applications, ROS‐induced protective autophagy promotes cell survival, especially in hypoxic tumors. Herein, X‐ray triggered nitrite (NO2−) is used for hypoxic prostate cancer therapy by inhibiting autophagy and inducing nitrosative stress based on an electrophilic zeolitic imidazole framework (ZIF‐82‐PVP). After internalization of pH‐responsive ZIF‐82‐PVP nanoparticles, electrophilic ligands and Zn2+ are delivered into cancer cells. Electrophilic ligands can not only consume GSH under hypoxia but also capture low‐energy electrons derived from X‐rays to generate NO2−, which inhibits autophagy and further elevates lethal nitrosative stress levels. In addition, dissociated Zn2+ specifically limits the migration and invasion of prostate cancer cells through ion interference. In vitro and in vivo results indicate that ZIF‐82‐PVP nanoparticles under X‐ray irradiation can effectively promote the apoptosis of hypoxic prostate cancer cells. Overall, this nitrosative stress‐mediated tumor therapy strategy provides a novel approach targeting hypoxic tumors.

01 Jul 2021·World NeurosurgeryQ4 · MEDICINE

Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review

Q4 · MEDICINE

Review

Author: Mansouri, Alireza ; Connor, James ; Padmanaban, Varun ; Kruser, Timothy J ; Hamidi, Nima ; Beg, Usman ; Madhani, Sarosh Irfan ; Tuanquin, Leonard C ; Snyder, Brianna Michelle

BACKGROUNDRadiation therapy (RT) is the cornerstone of management of malignant brain tumors, but its efficacy is limited in hypoxic tumors. Although numerous radiosensitizer compounds have been developed to enhance the effect of RT, progress has been stagnant. Through this systematic review, we provide an overview of radiosensitizers developed for malignant brain tumors, summarize their safety and efficacy, and evaluate areas for possible improvement.METHODSFollowing PRISMA guidelines, PubMed, EMBASE, Cochrane, and Web of Science were searched using terminology pertaining to radiosensitizers for brain tumor RT. Articles reporting clinical evidence of nonantineoplastic radiosensitizers with RT for malignant central nervous system tumors were included. Data of interest were presumed mechanism of action, median overall survival (OS), progression-free survival (PFS), and adverse events.RESULTSTwenty-two unique radiosensitizers were identified. Only 2/22 agents (fluosol with oxygen, and efaproxiral) showed improvement in OS in patients with glioblastoma and brain metastasis, respectively. A larger study was not able to confirm the latter. Improved PFS was reported with use of metronidazole, sodium glycididazole, and chloroquine. There was a wide range of toxicities, which prompted change of schedule or complete discontinuation of 9 agents.CONCLUSIONSProgress in radiosensitizers for malignant CNS tumors has been limited. Only 2 radiosensitizers have shown limited improvement in survival. Alternative strategies such as synthetic drug design, based on a mechanism of action that is independent of crossing the blood-brain barrier, may be necessary. Use of drug development strategies using new technologies to overcome past challenges is necessary.

01 Jan 2021·BioengineeredQ4 · BIOLOGY

Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model

Q4 · BIOLOGY

ArticleOA

Author: Zhou, Juying ; Shi, Weiqiang ; Li, Li

In this study, we construct a subcutaneous tumor mice model of U14 cells, observe the tumor growth, and detect the expression of Foxp3 and VISTA in cervical cancer tissues and adjacent tissues during CMNa-enhancing radiotherapy.From the 15th day, compared with the control group, the tumor volume changes in each treatment group were significant (P < 0.01). CMNa combined with radiotherapy had an interactive effect and a positive effect in inhibiting tumor volume growth. There was no significant difference in the expression of Foxp3 and VISTA in mouse cervical cancer tissues and adjacent tissues in each group. The Foxp3 level in the RT group was the highest, and the CMNa group was the lowest. The VISTA level of the CMNa+RT group was the highest, the RT group is followed by, and the Control group is the lowest. The Foxp3 level of the CMNa group did not change much at each different point. The Foxp3 level in RT and CMNa+RT group gradually decreased after a transient increase, and the VISTA level in the CMNa+RT group increased more.Our results show that CMNa can enhance the efficacy of radiotherapy, and at the same time can reduce the compensatory increase in regulatory T cell Foxp3 levels caused by radiotherapy, and reduce the radiotherapy response. However, in the course of the treatment of the two, there may be a substantial increase in the level of VISTA, and the combined application of VISTA inhibitors may increase the anti-tumor response.

100 Deals associated with Glycididazole Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Esophageal Carcinoma	China	Guangzhou Lifetech Pharmaceuticals Co. Ltd.	29 Nov 2002
Head and Neck Neoplasms	China	Guangzhou Lifetech Pharmaceuticals Co. Ltd.	29 Nov 2002
Lung Cancer	China	Guangzhou Lifetech Pharmaceuticals Co. Ltd.	29 Nov 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02721563 (ASTRO2017)	Phase 4	Esophageal Squamous Cell Carcinoma	-	CMNa + CCRT	(gqkdqtubmy) = qzxmflobei skhexmgxvg (ubjicwlgxl )	Positive	01 Oct 2017
				CCRT alone	(gqkdqtubmy) = lkzkxbfhlq skhexmgxvg (ubjicwlgxl )
ASTRO2016	Not Applicable	Hypoxia HIF1-Î± \| OPN	-	CMNa 171.9mg/kg	xzqqbhouie(gxpuvthckw) = ndslrhpkvu jlhpitpvuq (jebvtncnyy, 23.09â¼111.04) View more	Positive	01 Oct 2016
				CMNa 57.3mg/kg	xzqqbhouie(gxpuvthckw) = cyqbnhabzi jlhpitpvuq (jebvtncnyy, 25.69â¼113.01) View more